H ypertension is the single most important predisposing factor for cardiovascular and renal impairments and remains an important public health issue. The mechanisms involved in the pathogenesis of human essential hypertension are multifactorial and remain unknown.
H ypertension is the single most important predisposing factor for cardiovascular and renal impairments and remains an important public health issue. The mechanisms involved in the pathogenesis of human essential hypertension are multifactorial and remain unknown. 1 The majority of current therapeutics are targeted against the peripheral overactive renin-angiotensin system. 2 These therapies have clearly reduced the morbidity and mortality in hypertensive patients; however, the long-term prognosis remains poor, and new therapeutic approaches are needed. Although several factors have been implicated in the pathogenesis of salt-induced hypertension, recent studies have highlighted the role played by inflammatory cytokines in the brain. [3] [4] [5] [6] Kinins are a family of vasoactive proinflammatory peptides of the kallikrein-kinin system that mediate a variety of physiological actions related to cardiovascular homeostasis, inflammatory responses, and pain induction mechanisms. 7 Kinins, particularly bradykinin and lysyl-bradykinin (Lys-BK) or kallidin, are important mediators of inflammatory responses. 7 Physiological effects of kinins are mediated by 2 pharmacologically distinct G-protein coupled receptor subtypes, kinin B1 (B1R) and B2 (B2R) receptors. 8, 9 Bradykinin and Lys-BK are relatively selective ligands for the B2R, whereas bradykinin metabolites des-Arg9-BK and Lys-des-Arg9-BK are selective ligands for the B1R. 8, 9 Carboxypeptidase N enzymatically removes the carboxy-terminal arginine from BK, forming des-Arg9-BK. Typically, the B2R is constitutively expressed, whereas B1R expression is upregulated in the presence of cytokines and endotoxins or after tissue injury. 9, 10 Interestingly, unlike B2R, once B1R is activated by an agonist, it is not internalized or desensitized. 10 Thus, B1Rs are better equipped to mediate the chronic actions of the bradykinin system and represent a novel therapeutic target for chronic inflammatory diseases.
Observations from clinical and experimental studies suggest an important role for kinins and its receptors in the maintenance of normotension and the development of hypertension. [11] [12] [13] [14] [15] However, the role of B1R expression in the cardiovascular system is still poorly understood. Evidence has been presented that B1R blockade contributes to the protective effects of angiotensinconverting enzyme inhibitors in mice after myocardial infarction 16 and in diabetic nephropathy. 17 On the contrary, significant upregulation of B1R gene expression was observed in cardiac and renal tissues of salt-dependent and renovascular hypertensive animals. 13 Upregulation of B1R and increased systolic pressure were observed in a rat model of insulin resistance induced by glucose feeding, which was prevented by treatment with B1R antagonist. 18 Acute blockade of B1R using specific antagonist or antisense oligodeoxynucleotides infusion decreased blood pressure (BP) in spontaneously hypertensive (SH) but not in WistarKyoto (WKY) rats. 19 These studies suggest that B1R expression may play a role in the pathogenesis of hypertension. However, studies addressing the effect of chronic blockade of B1R on neurogenic hypertension have not been performed. Despite the body of evidence that supports a role for the kinin B1R in hypertension, the mechanisms through which the B1R participates in the pathogenesis of hypertension remain unknown. Therefore, in the present study, we determined the effects of kinin B1R deletion and brain specific antagonism of the B1R on deoxycorticosterone acetate (DOCA)-salt hypertension-a neurogenic hypertension model. Additionally, we examined the role of B1R in neuroinflammation, sympathetic activation, baroreflex sensitivity, and the cellular and molecular mechanisms involved during neurogenic hypertension. The specific objectives of the present study were to investigate the following: (1) the involvement of B1R activation in the brain cardiovascular regulatory centers in hypertension, (2) the role of B1R blockade either globally or specifically in the brain on hypertension, and (3) elucidate the molecular signaling mechanisms activated by B1R in the pathogenesis of neurogenic hypertension.
Methods
A detailed Methods section is available in the online-only Data Supplement.
Animals
Mice were housed in a temperature-and humidity-controlled facility under a 12-hour dark/light cycle and fed standard mouse chow and water ad libitum. The experiments were performed on adult male mice (12-16 weeks old). B1R knockout (B1RKO) mice were a kind gift from Dr Michael Bader (Charité Hospital, Berlin, Germany) and originated from 10 generations of backcrossing of an initially mixed genetic background (129/ Sc and C57Bl/6) with C57Bl/6 mice. 20 Wild-type (WT) C57Bl/6J mice (stock number: 000664) were purchased from the Jackson Laboratory. All animal studies were approved by the Louisiana State University Health Sciences Center-New Orleans Animal Care and Use Committee (IACUC #3271) and were performed in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals.
Data Analysis
Data are presented as mean±SEM. Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software). Experiments involving 2 groups were compared using unpaired, 2-tailed t tests. Multiple comparisons were made using 1-or 2-way ANOVA, followed by Bonferroni post hoc analysis or Tukey multiple comparisons test, as appropriate. Mean arterial pressure (MAP) data were analyzed by 2-way repeated measures ANOVA with Tukey multiple comparisons test. Differences were considered statistically significant at P<0.05.
Results

Kinin B1R Expression is Upregulated in the Brain of Hypertensive Mice
To determine whether B1R expression is involved in hypertension, we first performed immunohistochemistry for this receptor in the brain of mice submitted to the DOCA-salt paradigm. Immunostaining of coronal brain sections with a B1R-specific antibody showed a dramatic upregulation of the receptor expression in the hypothalamus of hypertensive mice compared with control mice ( Figure 1A ). In addition, we performed double immunolabeling of B1R and MAP2 (microtubule associated protein 2)-a neuronal marker-which showed colocalization of B1R immunoreactivity within neurons, suggesting that B1R expression was upregulated in neurons during hypertension ( Figure S1 in the online-only Data Supplement). Gene expression assessed by real-time reverse transcriptionpolymerase chain reaction revealed that B1R mRNA was significantly upregulated in hypothalamus and brain stem, notably the paraventricular nucleus (PVN) and rostral ventrolateral medulla of DOCA-salt-treated hypertensive mice when compared with sham-treated controls ( Figure 1B ; P<0.01). However, B1R gene expression was higher in the PVN than in the rostral ventrolateral medulla. Western blot analysis revealed that B1R protein levels in the hypothalamus and PVN were also significantly increased in DOCA-salt hypertensive mice compared with controls ( Figure 1C ; P<0.01). B1R mRNA expression was increased at days 7, 14, and 21 of DOCA-salt treatment compared with sham mice ( Figure 1D ; P<0.01) suggesting an early upregulation of B1R, which remained elevated throughout the study. In addition, bradykinin levels in the plasma and hypothalamus ( Figure S2 ; P<0.01) were significantly increased in DOCA-salt-treated mice compared with sham mice. Gene and protein expression of carboxypeptidase N, which converts bradykinin into the B1R endogenous ligand des-Arg9-BK, were significantly enhanced in the hypothalamic PVN of DOCAsalt-treated mice ( Figure S2 ; P<0.01), confirming the central activation of this pathway in hypertension.
Kinin B1R Deletion Attenuates Neurogenic Hypertension by Preserving Autonomic Function and Baroreflex Sensitivity
To further determine the role of B1R in DOCA-salt hypertension, we used B1R global KO mice ( Figure S3 ) and WT controls. MAP was similar in both WT and B1RKO mice at baseline (WT, 102±2 versus B1RKO, 104±5 mm Hg; P>0.05) without significant change during the 24-hour period (Figure 2A ). Three weeks of DOCA-salt treatment ( Figure 2B ) significantly increased MAP in WT mice (138±3 mm Hg; P<0.01 versus sham, 102±2 mm Hg). However, this increase was blunted in B1RKO mice (121±2 mm Hg; P<0.05 versus WT+DOCA), suggesting that B1Rs are required for the development of DOCA-salt-induced hypertension. Previous studies from our laboratory and others showed that DOCAsalt hypertension-a model of neurogenic hypertension-is associated with autonomic dysfunction and elevated sympathetic activation. 4, 21 Autonomic function was identical at baseline between sham-treated WT and B1RKO mice ( Figure 2C through 2E). DOCA-salt administration resulted in significant increases in both cardiac (increased bradycardia to propranolol, −145±21 bpm; P<0.01 versus sham) and vascular (decreased MAP to chlorisondamine, −88±7 mm Hg; P<0.01 versus sham) sympathetic drive, as well as reduction of vagal tone (reduced tachycardia to atropine, +111±8 bpm; P<0.01 versus sham) in WT mice, which were normalized in B1RKO December 2017 mice (−72±13 bpm, −59±3 mm Hg, and +165±6 bpm, respectively; P<0.01 versus WT+DOCA).
The baroreceptor reflex is the main mechanism involved in the beat-to-beat maintenance of BP within a normal range, and we previously showed that its sensitivity is impaired in DOCA-salt hypertension. 5 To assess the effects of B1R deletion on baroreflex function, we determined spontaneous baroreflex sensitivity using the sequence method. Spontaneous baroreflex sensitivity was significantly reduced in WT+DOCA mice compared with sham ( Figure 2F ). However, B1RKO mice showed no impairment of spontaneous baroreflex sensitivity during DOCA-salt treatment ( Figure 2F ), further suggesting that B1R contributes to impaired autonomic and baroreflex functions in hypertension. In addition, DOCA-salt treatment resulted in sympathoexcitation in WT mice, as indicated by significantly increased plasma (13±1 ng/mL; P<0.05 versus sham, 6±1 ng/ mL) and urinary (299±23 ng/mL; P<0.05 versus sham, 151±7 ng/mL) norepinephrine levels, but these increases were blunted in B1RKO mice with DOCA (4±1 and 172±30 ng/mL, respectively; P<0.05 versus WT+DOCA; Figure S4 ). Furthermore, in WT mice, DOCA-salt treatment led to a significant increase in urinary arginine vasopressin, measured by the C-terminal portion of the arginine vasopressin precursor, copeptin. This increase was blunted in B1RKO with DOCA-salt treatment ( Figure S4 ). 
Kinin B1R Blockade Reduces DOCA-Salt-Induced Neuroinflammation
To understand the contribution of B1R activation to the production of inflammatory markers, we extended our study by measuring proinflammatory cytokines and chemokines in hypothalamic PVN homogenates after 3 weeks of sham or DOCA-salt hypertension. In WT DOCA-salt hypertensive mice, protein levels of IL-1β (interleukin 1β), TNF (tumor necrosis factor), MCP-1 (monocyte chemoattractant protein 1), IFN-γ (interferon-γ), RANTES (regulated on activation, normal T cell expressed and secreted protein), and G-CSF (granulocyte-colony stimulating factor) were significantly increased indicating elevated neuroinflammation ( Figure 3) . However, these increases were completely abrogated in B1RKO+DOCA mice, suggesting that B1R knockdown reduces neuroinflammation during hypertension.
Kinin B1R Blockade Blunts DOCA-Salt-Induced Oxidative Stress
To elucidate the possible mechanisms involved in the attenuation of hypertension after B1R knockdown, we investigated . DOCA implanted subcutaneously and combined with 1% salt as drinking solution induced a progressive rise of MAP in sham-treated controls that was attenuated in B1RKO mice (B, n=8 mice/group, repeated measures 2-way ANOVA, *P<0.01 vs sham, †P<0.05 vs WT+DOCA). After 21 d of DOCA-salt treatment, autonomic function was assessed pharmacologically by determining the changes in MAP (ΔMAP) and heart rate (ΔHR) after ip injections of a β-blocker (propranolol: 4 mg/kg, cardiac sympathetic tone, C), ganglionic blocker (chlorisondamine: 5 mg/kg, vascular sympathetic tone, D), and muscarinic antagonist (atropine: 1 mg/kg, cardiac parasympathetic tone, E). Spontaneous baroreceptor reflex sensitivity (SBRS) was calculated using the sequence method (F) and was improved in B1RKO mice treated with DOCA compared with WT mice. n=6 to 8 per group. Data are presented as mean±SEM. Two-way ANOVA, *P<0.01 vs sham, †P<0.01 vs WT+DOCA. December 2017 oxidative stress markers that we previously reported as elevated in DOCA-salt hypertension. 5 Notably, we investigated the gene and protein expression of Nox2-a catalytic subunit of NADPH oxidase and inducible NO synthase (iNOS) in the PVN. Real-time reverse transcription-polymerase chain reaction analysis showed significant increases in Nox2 and iNOS gene expression in the PVN of WT+DOCA mice but not in B1RKO+DOCA mice ( Figure S5 ). Western blot analysis revealed that protein levels of Nox2 and iNOS were significantly increased in the PVN after 3 weeks of DOCA-salt hypertension in WT mice. In contrast, these proteins showed blunted expression in B1RKO after DOCA treatment, indicating decreased oxidative stress in the brain ( Figure 4A and 4B).
Kinin B1R Blockade Reduces Activation of ASK1-JNK-ERK1/2 Pathway
ASK1 (apoptosis signal regulating kinase 1) is activated in response to various cytotoxic stresses, including inflammation and oxidative stress, and is required for sustained activation of JNK (c-Jun N-terminal kinase) and p38 MAP kinases. In this study, we examined whether B1R activation can activate the ASK1-JNK-ERK1/2 signaling pathway in neurogenic hypertension. DOCA-salt treatment for 3 weeks significantly increased the phosphorylation of ASK1 in WT mice but not in B1RKO mice ( Figure 4C ). Next, we examined whether B1Rs are involved in activating MAPK (mitogen activated protein kinase) signaling. Phosphorylation at residues Thr 
Kinin B1R Blockade Prevents NF-κB Activation
To determine the involvement of B1R-mediated ASK1-JNK-ERK1/2 signaling in NF-κB (nuclear factor κB) activation, we assessed NF-κB p65 expression in the PVN nuclear and cytoplasmic fractions using Western blot. In WT mice, DOCA-salt hypertension significantly increased the expression of nuclear NF-κB p65 ( Figure 5A ) and decreased cytoplasmic NF-κB p65 ( Figure 5B ) suggesting a translocation of NF-κB p65 subunit from cytosol to nucleus. In contrast, in B1RKO mice with DOCA salt, there was no significant difference in nuclear and cytoplasmic NF-κB p65 expression when compared with sham mice, suggesting a lack of NF-κB activation in these animals ( Figure 5 ).
Blockade of B1R Within the Brain Attenuates Hypertension, Improves Autonomic Function, and Reduces Neuroinflammation
Although our studies using B1RKO mice provided evidence that B1R genetic deletion attenuates the development of neurogenic hypertension, deletion of a gene may result in compensatory changes in other vasoactive factors during ontogenesis, whose altered status may contribute to the phenotype of transgenic mice. It has been reported that deletion of kinin receptor gene can affect specific tissues differently, resulting in downregulation or upregulation of related receptors. 13 Real-time polymerase chain reaction results show that genetic deletion of B1R results in compensatory increase in B2R gene expression ( Figure S6 ). To rule out contribution of B2R in the beneficial effects of B1R gene deletion, we used a pharmacological approach to examine the role of B1R in the brain during hypertension. We used R715-a specific antagonist to block B1R within the brain of WT mice with or without DOCA-salt hypertension. In line with our findings in B1RKO mice, chronic intracerebroventricular infusion of R715 led to a significant attenuation of DOCA-salt hypertension ( Figure 6A ).
In addition, the DOCA-salt hypertension-induced cardiac dysautonomia was prevented, sympathetic drive to the vasculature was reduced, whereas vagal tone and baroreflex function were restored by R715 treatment (Figure 6B through 6E) . Furthermore, ruling out a peripheral effect of this antagonist, subcutaneous infusion of same dose of R715 for 3 weeks with Figure 5 . Kinin B1 receptor (B1R)-mediated downstream signaling involves NF-κB (nuclear factor κB) activation. NF-κB p65 protein expression was quantified using Western blot in brain hypothalamic nuclear and cytosolic fractions from wild-type (WT) and B1R knockout (B1RKO) mice after a 3-wk deoxycorticosterone acetate (DOCA)-salt or sham treatment. Protein expression was normalized to housekeeping genes lamin (nuclear proteins) and tubulin (cytosolic proteins). NF-κB p65 levels were significantly increased in nuclear fractions (A) and decreased in cytosolic fractions (B) in hypertensive DOCA-salt-treated mice, indicating activation and translocation of NF-κB into the nucleus. However, no change in NF-κB p65 expression was observed in B1RKO mice with DOCA salt compared with sham, suggesting that B1R gene deletion prevented NF-κB activation. Data are presented as mean±SEM. n=6 per group. Two-way ANOVA, *P<0.05 vs WT+sham, †P<0.05 vs WT+DOCA. DOCA salt did not prevent the development of hypertension ( Figure S7 ). The DOCA-salt hypertension-induced increases in urinary and plasma norepinephrine and urinary copeptin levels were blunted by treatment with R715 suggesting decreased sympathetic drive in these mice ( Figure S8 ). We also observed that similar to our B1RKO mice, R715 treatment reduced the inflammatory response within the brain, as evidenced by decreased expression of cytokine and chemokines in the PVN ( Figure S9A ). In addition, central R715 treatment also reduced oxidative stress in the brain as indicated by reductions in Nox2 and iNOS mRNA expression in the PVN (Figure S9B and S9C). These data provide strong evidence that B1R expression within the brain plays a critical role in maintaining the functionality of baroreflex and autonomic regulations and reduction in neuroinflammation and oxidative stress during the development of neurogenic hypertension.
Discussion
The major findings of our present study are that (1) B1R expression is significantly upregulated in brain cardiovascular regulatory nuclei during DOCA-salt hypertension; (2) global deletion of B1R protected mice from the development of DOCA-salt-induced hypertension; (3) importantly, selective pharmacological blockade of B1R in the brain attenuated DOCA-salt-induced hypertension suggesting a central origin mechanism; (4) B1R blockade prevented autonomic dysfunction, reduced neuroinflammation, and decreased oxidative stress, thereby blunting neurogenic hypertension; (5) the beneficial effects of B1R deletion are mediated by ASK1-JNK-ERK1/2 and NF-κB pathway inhibition in the PVN. Our study offers new insights into the possible signaling pathways of kinin B1R activation in the brain and provides the first evidence, to our knowledge, of a central role for B1R-mediated inflammatory pathway in the pathogenesis of DOCA-salt hypertension.
Despite the body of evidence supporting a role for B1R activation in hypertension, the beneficial effects of B1R blockade on hypertension remain inconclusive. It was previously reported that neither the B1R agonist des-Arg9-BK nor the B1R antagonist Leu8-des-Arg9-BK injected acutely into the fourth ventricle modified BP in SH or WKY rats. 22 In contrast, another study reported that the same B1R antagonist, Leu8-des-Arg9-BK, injected into the lateral ventricle (intracerebroventricular) caused a long-lasting reduction in BP and heart rate in SH but not in WKY rats. 23 Emanueli et al 19 also reported that intracerebroventricular activation of B1R in SH and WKY rats evokes increases in BP, whereas intracerebroventricular injection of the B1R antagonist R715 causes a mild decrease of BP (−14 mm Hg) within 15 minutes in SH rats. On the contrary, Cloutier et al 24 showed that intracerebroventricular injection of R715 failed to alter MAP and heart rate for a period ≤24 hours post-injection in SH and WKY rats. Therefore, to elucidate the mechanisms of chronic B1R blockade on hypertension (and to circumvent the lack of tissue-specific deletion mouse models), we used 2 complementary approaches, genetic deletion and pharmacological antagonism, to prevent B1R activation selectively and chronically. The B1R global KO mouse is normotensive compared with WT controls and shows a clear nycthemeral variation in BP recorded continuously with telemetry during a period of 24 hours. Our data clearly demonstrate that DOCA-salt-induced hypertension is attenuated in B1R-deficient mice and suggest that B1R is indeed responsible for the development of neurogenic hypertension. In addition, to investigate the importance of B1R in central regulation of BP, we used a pharmacological approach. Infusion of a specific B1R antagonist R715 chronically through intracerebroventricular route for 3 weeks resulted in attenuation of DOCAsalt hypertension. In contrast, the same dose of B1R antagonist when administered systemically did not prevent the development of hypertension. Similar to B1RKO mice being normotensive, central treatment with R715 for 3 weeks did not alter the BP in control sham mice, implying that at baseline, B1R are not involved in the physiological control of BP. Taken together, these data suggest that the activation of B1R in the brain is critical for the development of hypertension, and its blockade attenuates the development of the disease. Although B1RKO mice or the B1R antagonist resulted in an attenuated hypertension, the BP was not completely reduced to control level, confirming that other pathways may be involved, independently of B1R. Interaction between the kinin-kallikrein system and the renin-angiotensin system is well known, and future studies are warranted to evaluate the combination of kinin B1R blockade with renin-angiotensin system blockers.
To the best of our knowledge, this is the first demonstration that B1R gene and protein expression are significantly increased in brain nuclei critical for BP regulation, during low renin DOCA-salt hypertension model, which is clinically relevant to black patients and patients with type 2 diabetes mellitus. Previous studies have reported elevated densities of B1R-binding sites 24 or increased B1R mRNA expression 25 in the hypothalamus of 12-to 13-week-old SH rats when BP was significantly higher compared with WKY rats. Indeed, our time course experiments show that B1R mRNA expression was significantly increased at 7 days of DOCA-salt treatment, which coincided with a maximum rise in MAP and this B1R expression remained elevated during the course of the experiment. Moreover, increase in bradykinin levels coupled with increased expression of carboxypeptidase N might be responsible for the elevated des-Arg9-BK formation leading to B1R activation. In fact, it has been previously shown that once B1R is activated by an agonist, it is not internalized or desensitized, 7 and in the inflammatory context, the B1R agonist is able to upregulate the expression of its own receptor via the activation of the transcription factor NF-κB. 26 These findings suggest that once B1R is activated, it can create a vicious cycle of its own activation leading to lasting effects.
Recently, it has become apparent that inflammation plays a pivotal role in the development of hypertension. Proinflammatory cytokines, such as tumor necrosis factor-α 27 , interleukin-1β, 27, 28 and IL-6, 28, 29 have been reported to be increased in hypertensive patients. Recent studies from our group and others demonstrate a link between inflammation and activated renin-angiotensin system in neurogenic hypertension. [3] [4] [5] 30 Inflammation in the brain involves primarily the activation of microglia. We have previously shown that neurogenic hypertension involves activation of microglia in the PVN, and indeed inhibition of PVN microglia activation fully abolishes angiotensin-II-induced hypertension. 30 Expression of kinin B1R in microglia and increase in inflammatory cytokine production after activation of B1R were reported previously. 31, 32 Furthermore, B1R expression is also induced by various proinflammatory cytokines and growth factors, such as epidermal growth factor. 9 In the present study, we demonstrate that in DOCA-salt hypertension, elevated B1R expression is correlated with elevated inflammation, as indicated by increased protein levels of cytokines and chemokines in PVN. Importantly, B1R gene deletion was able to prevent inflammation in PVN, suggesting that B1R activation is important in initiating the inflammatory response observed in neurogenic hypertension. Previous findings have emphasized the role of inflammatory cytokines in the PVN in mediating sympathoexcitation and autonomic function during various cardiovascular diseases, including hypertension. 4, 5, 30 In our study, we found that B1R gene deletion reversed the DOCAsalt hypertension-induced autonomic dysfunction and sympathoexcitation, and improved baroreflex sensitivity, suggesting a central role for B1R activation during neurogenic hypertension.
We previously showed that in DOCA-salt hypertension, elevated neuroinflammation could induce oxidative stress and activate MAPK-mediated signaling mechanisms. 4 ,5 ASK1 was identified as a ROS-sensitive MAPK kinase, which activates December 2017 the JNK and p44/42 MAPK (ERK1/2) cascade. 33 Activation of kinin B1R with a selective agonist either in vitro or in vivo enhanced aortic superoxide anion production through activation of NADPH oxidase, which was abolished by apocynin-a selective inhibitor of NADPH oxidase. 15 It has been previously reported that B1R activation involves NF-κB-mediated signaling mechanisms in human 34 and rat 35 vascular smooth muscle cells. In this study, B1R blockade significantly inhibited oxidative stress markers, including Nox2 and iNOS, phosphorylation of ASK1, JNK, and ERK1/2 within the PVN. Furthermore, B1R blockade also prevented the activation of NF-κB-an early transcriptional factor that modulates gene expression initiating rapid inflammatory response. Here, we provide the first evidence that the activation of this ASK1-MAPK NF-κB-mediated inflammatory signaling pathway is dependent on B1R activation. Thus, we might suggest that ASK1, JNK, ERK1/2, and NF-κB are acting downstream of B1R activation, mediating the expression of proinflammatory molecules in a feed-forward fashion and are responsible for driving the neuroinflammation and sympathoexcitation, thereby contributing to neurogenic hypertension ( Figure S10 ). However, a limitation of our study is the inability to determine whether these signaling pathways are activated within 1 cell type or whether activation occurs simultaneously within multiple cell types (eg, within neurons and microglia).
Because DOCA-salt hypertension is mainly driven by an alteration in central mechanisms regulating BP, 21 we further investigated the importance of kinin B1R in BP control, using a brain-targeted pharmacological approach. Chronic intracerebroventricular infusion of R715-a B1R specific antagonistattenuated the development of DOCA-salt hypertension. On the contrary, subcutaneous infusion of R715 for 3 weeks with DOCA salt did not prevent the development of hypertension, suggesting that this mechanism is not because of peripheral activation of compensatory mechanisms. In addition, hypertension-induced inflammation, oxidative stress, cardiac and vascular dysautonomia were prevented, and baroreflex function was restored by intracerebroventricular R715 treatment. These data clearly support a central role for B1R activation in neurogenic hypertension. Using these 2 different approaches, genetic KO animal model and pharmacological blockade of B1R model allowed us (1) to confirm the importance of B1R in neurogenic hypertension, (2) to study the brain specificity of the effects of B1R blockade, and (3) to study the long-term effect of B1R deletion before the onset of hypertension in KO mice versus blockade of B1R in parallel to the development of hypertension.
Perspectives
Dysregulation of the kallikrein-kinin system and its receptors is involved in many pathological conditions and cardiovascular diseases that are associated with or induced by inflammation. 8, 13, 31 In the last decade, numerous seminal works showed evidence for immune cell infiltration and inflammation in the brain in the pathogenesis of hypertension. 3, 30, [36] [37] [38] Patients with essential hypertension exhibit a significant upregulation of B1R gene expression in peripheral monocytes, leading to functional changes and the development of target-organ damage. 39 Recent evidence suggests that novel orally active, selective nonpeptide B1R antagonists are effective in the treatment of various in vivo models of inflammation and insulin resistance. [40] [41] [42] It has been postulated that the kinin receptor signaling pathway may act as a molecular link between changes in hemodynamic forces and the activation of inflammatory pathways. 39 Our data clearly show the beneficial effect of central B1R blockade in reducing inflammation and preventing the development of hypertension. Accordingly, Kinin B1R blockade may provide a novel strategy to reduce neuroinflammation, oxidative stress, and sympathoexcitation in neurogenic hypertension.
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